Taken together, miR-34c could inhibit osteogenic differentiation and calcification of VICs by suppressing the STC1/JNK signaling pathway in CAVD, making miR-34c a novel therapeutic target for the treatment of CAVD. The gene discussed is MAPK8; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.